Clinical Trial Update: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting completion of Phase 1/2 study evaluating EBV-specific anti-PD1 TCR-T cells for EBV-positive head and neck squamous cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• EBV-Specific Anti-PD1 TCR-T Cells

Snippet

Sponsor: Xinqiao Hospital of Chongqing | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED